Shire Submits Mesavance NDA For Ulcerative Colitis
This article was originally published in The Pink Sheet Daily
If approved, Mesavance would be the first once-daily mesalamine treatment for UC.
You may also be interested in...
Delay allows FDA to review supplemental Phase I dose absorption study for ulcerative colitis treatment.
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue